News
Public · Published
ResMed Price Target Raised 3.6% to A$37.50/Share by Barrenjoey
Barrenjoey raised its price target for ResMed by 3.6% to A$37.50 per share. The supplied article provides no further details about the reasons for the change or any accompanying change to its view of the company.
Published:
Updated:
What happened
Barrenjoey raised its price target for ResMed by 3.6% to A$37.50 per share. The supplied article provides no further details about the reasons for the change or any accompanying change to its view of the company.
Confirmed
Global impact / market context
A higher price target signals that Barrenjoey sees more potential value in ResMed shares than before, but it is an analyst estimate, not a company forecast or guarantee. Without the reasoning or earnings assumptions, investors cannot tell what business factors support the increase.
Analyst inference
The report gives only the revised target and its percentage increase; it does not state ResMed’s share price, the previous target, or the analyst’s rationale. Therefore, it is not possible to judge the implied gap between the target and the current price.
Analyst inference
What to watch
- Look for Barrenjoey’s full rationale and assumptions, especially whether it cites expected sales, costs, or profit per sale; those details would show what supports its higher valuation. Analyst inference
- Compare later ResMed business updates with any assumptions disclosed by Barrenjoey; changes in sales or costs could strengthen or weaken the case for the raised target. Analyst inference
- Check whether other analyst targets or recommendations change, since a broader shift in estimates could affect investor positioning; no such responses are reported in the supplied article. Analyst inference
Evidence
- Original source link unavailable